{"title":"Pharmacokinetic Analysis","markdown":{"yaml":{"title":"Pharmacokinetic Analysis","author":"SEOYEON CHOI","date":"2023-06-09","bibliography":"ref.bib","categories":["Pharmacokinetic Analysis"]},"headingText":"Import","containsRefs":false,"markdown":"\n\n> Pharmacokinetic Analysis\n\nRef: [Winnonlin Guide 8.3](https://onlinehelp.certara.com/phoenix/8.3/responsive_html5_!MasterPage!/WinNonlin%20User%27s%20Guide.pdf), [Design and Analysis of Bioavailability and Bioequivalence Studies](https://books.google.co.kr/books?hl=ko&lr=&id=KtKJFGJeV3MC&oi=fnd&pg=PP1&dq=Design+and+analysis+of+bioavailability+and+bioequivalence+studies+,+Third+edition,+Chapman+%26+Hall&ots=scXq3Y2TPA&sig=S_FTX9fEmubxjz2RlouUnbWL7f0#v=onepage&q=Design%20and%20analysis%20of%20bioavailability%20and%20bioequivalence%20studies%20%2C%20Third%20edition%2C%20Chapman%20%26%20Hall&f=false), [2×k 교차설계법에서\n생물학적 동등성 추가시험의 통계적 절차](http://koreascience.or.kr/article/JAKO201436351074280.pdf), [식품의약품안전처 의약품 동등성 시험 기준](https://www.law.go.kr/LSW/admRulLsInfoP.do?admRulSeq=2100000129149)\n\n\n# PK Analysis\n\n## Generic Medicine\n\n- a generic medicine works in the same way and provides the same clinical benefit as the brand-name medicine.^[https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers]\n\n- 특허기간이 만료된 오리지널 의약품과 주성분, 함량 및 제형이 동일하게 복제된 제네릭 의약품은 생물학적 동등성 (이하‘생동성’이라 한다)시험을 통해 오리지널 의약품과 약효가 동등하다는 것을 입증 하면 시장에 진입할 수 있다.^[식품의약품안전처 의약품 동등성 시험 기준]\n\n- 제네릭 의약품을 승인 받기 위해 생동성 시험을 거쳐야 한다\n\n## Bioequivalent\n\n- Drug companies must submit an abbreviated new drug application (ANDA) to FDA for approval to market a generic drug that is the same as (or bioequivalent to) the brand product^[https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers]\n\n- 생동성 시험은 제재학적으로 동등한 두 제제의 동등성 입증을 위해 실시하는 샐체내 실험으로, 통계학적으로 두 제제의 생체이용률의 유사성을 비교하는 시험을 의미한다.[@우화형20142]\n\n## Parameter\n\n- $AUC_t$\n    - Area under the curve from the time of dosing to the time of the last measurable (positive) \nconcentratio\n    - 약물 투여 시점부터 마지막으로 측정 가능한 (양수인) 농도까지의 면적인 (Area Under the Curve, AUC)는 약동학에서 사용되는 일반적인 파라미터\n    - 시간에 따른 약물 노출의 범위를 추정하는 데 사용\n    - 해당 기간 동안 혈중에서의 누적된 약물 농도를 나타냄\n\n - $C_{max}$    -  Maximum observed concentration, occurring at time Tmax, as defined above.\n    -  $T_{max}$에서의 최대 농도\n - $T_{max}$\n    - Time of maximum observed concentration. For non-steady-state data, the entire curve is considered. If the maximum observed concentration is not unique, then the first maximum is used.\n    - 최대 혈중 농도가 관찰된 시간\n    - 유일한 값이 아닌 경우 첫번재 값 사용\n \n- $\\lambda_z$\n    - First-order rate constant associated with the terminal (log-linear) portion of the curve. \nEstimated by linear regression of time vs. log concentration\n    - 곡선의 말단(로그-선형) 부분과 관련된 1차 속도상수는 시간 대 로그 농도의 선형 회귀를 통해 추정\n    - 곡선의 로그-선형 영역에서 시간과 로그 농도 간의 선형 관계를 분석하여 얻어진 1차 속도상수\n    - 약동학 데이터의 로그-선형 부분에서 시간 대 로그 농도의 관계를 선형 회귀하여 추정된 1차 속도상수를 의미.\n- $ln(2)/\\lambda_z$\n    -  Terminal half-life\n\n- $Tau$\n    -  Available in the Dosing Used results worksheet for steady-state data. The (assumed equal) dosing interval for steady-state data.\n    -  반복 투여하는 연구에서 반복투여하는 간격\n    -  예) 12시간 간격으로 하루에 두 번 투여시, tau = 12\n\n- $AUC_{TAU}$\n    - The partial area from dosing time to dosing time plus Tau. See “Partial area calculation”\n    - for information on how it is computed\n    - tau간격 별로 혈중 농도 곡선 하 면적.\n\n-$\\text{ Swing}$: Cmax – Cmn/Cmin\n\n-$\\text{ Fluctuation}$ \n\n- 100(Cmax – Cmin)/Cavg\n-  where Cmin and Cmax were obtained between dosing time and dosing time plus Tau\n- 약물 농도의 최소값($C_{min}$)과 최대값($C_{max}$) 사이의 변동을 약물 투여 간격 내에서 평균 농도($C_{avg}$)에 대한 백분율로 나타내는 약동학적 파라미터 .\n\n\n\n약동학 파라메터 산출 프로그램 윈놀린 가이드 참고^[https://onlinehelp.certara.com/phoenix/8.3/responsive_html5_!MasterPage!/WinNonlin%20User%27s%20Guide.pdf]\n\n- page 146 정도부터 파라메터 설명 및 계산법 확인\n\n아래는 식품의약품 안전처 규칙 내용 중 일부\n\n- AUCt: 투약시간부터 최종 혈중농도 정량 시간 t까지의 혈중농도-시간곡선하면적\n- AUC∞ : 투약시간부터 무한시간까지의 혈중농도-시간곡선하면적 (AUC∞ = AUCt + Ct/λZ\n- Ct : 최종정량농도\n- λZ : 말단 소실 정수\n- AUCt/AUC∞ : AUCt의 AUC대한 비\n- t1/2β : 소실 반감기\n- AUCτ : 정상상태의 투여간격τ중의 혈중농도-시간 곡선하면적\n- Cmax :최고혈중농도\n- Css,max정상상태의 최고혈중농도\n- Css,m: 정상상태의 최저혈중농도\n\n**동등성 기준 : Tmax를 제외한 대조약과 시험약의 비교평가항목치를 로그변환하여 통계처리 하였을 때, 로그변환한 평균치 차의 90% 신뢰구간이 log 0.8에서 log 1.25 이내이어야 한다**\n\n## 2 x 2 Crossover Design\n\n현재 식품의약품 안전처에서는 두 제제의 생동성 평가 방법으로 2 x 2 교차설계법을 이용하여 두 제제의 생체이용률의 평균을 비교하는 방법 사용\n\n|    | Period 1 | Period 2  |\n|:----:|:----------:|:-----------:|\n|Sequence 1| Reference|Test|\n|Sequence 2|Test|Reference|\n\n$$y_{jkl} = \\mu + g_j + S_{l(j)} + p_k + \\pi_{jk} + \\epsilon_{jkl}$$\n\n$$j = 1,2; k = 1,2; l=1,2, \\dots, n_{1j}$$\n\n$$S_{l(j)} \\sim iid N(0,\\sigma^2_s) , \\epsilon_{jkl} \\sim iid N(0, \\sigma^2_\\epsilon)$$\n\n### 혈중 농도 곡선 예시\n\n사다리꼴 공식으로 AUC 계산\n\n데이터 설명\n\n- Subject: 대상자\n- Sequence: 순서군\n- Period: 시기군\n- Concentration: 혈중농도\n- Treatment: 치료군\n\n`해석`\n\n- Trearmet의 p값은 0.05보다 큼. 치료 효과는 유의하지 않다.\n- Period의 p값은 0.05보다 큼, 시기효과는 유의하지 않다.\n- Sequence의 p값은 0.05보다 큼, 순서효과는 유의하지 않다.\n","srcMarkdownNoYaml":"\n\n> Pharmacokinetic Analysis\n\nRef: [Winnonlin Guide 8.3](https://onlinehelp.certara.com/phoenix/8.3/responsive_html5_!MasterPage!/WinNonlin%20User%27s%20Guide.pdf), [Design and Analysis of Bioavailability and Bioequivalence Studies](https://books.google.co.kr/books?hl=ko&lr=&id=KtKJFGJeV3MC&oi=fnd&pg=PP1&dq=Design+and+analysis+of+bioavailability+and+bioequivalence+studies+,+Third+edition,+Chapman+%26+Hall&ots=scXq3Y2TPA&sig=S_FTX9fEmubxjz2RlouUnbWL7f0#v=onepage&q=Design%20and%20analysis%20of%20bioavailability%20and%20bioequivalence%20studies%20%2C%20Third%20edition%2C%20Chapman%20%26%20Hall&f=false), [2×k 교차설계법에서\n생물학적 동등성 추가시험의 통계적 절차](http://koreascience.or.kr/article/JAKO201436351074280.pdf), [식품의약품안전처 의약품 동등성 시험 기준](https://www.law.go.kr/LSW/admRulLsInfoP.do?admRulSeq=2100000129149)\n\n# Import\n\n# PK Analysis\n\n## Generic Medicine\n\n- a generic medicine works in the same way and provides the same clinical benefit as the brand-name medicine.^[https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers]\n\n- 특허기간이 만료된 오리지널 의약품과 주성분, 함량 및 제형이 동일하게 복제된 제네릭 의약품은 생물학적 동등성 (이하‘생동성’이라 한다)시험을 통해 오리지널 의약품과 약효가 동등하다는 것을 입증 하면 시장에 진입할 수 있다.^[식품의약품안전처 의약품 동등성 시험 기준]\n\n- 제네릭 의약품을 승인 받기 위해 생동성 시험을 거쳐야 한다\n\n## Bioequivalent\n\n- Drug companies must submit an abbreviated new drug application (ANDA) to FDA for approval to market a generic drug that is the same as (or bioequivalent to) the brand product^[https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers]\n\n- 생동성 시험은 제재학적으로 동등한 두 제제의 동등성 입증을 위해 실시하는 샐체내 실험으로, 통계학적으로 두 제제의 생체이용률의 유사성을 비교하는 시험을 의미한다.[@우화형20142]\n\n## Parameter\n\n- $AUC_t$\n    - Area under the curve from the time of dosing to the time of the last measurable (positive) \nconcentratio\n    - 약물 투여 시점부터 마지막으로 측정 가능한 (양수인) 농도까지의 면적인 (Area Under the Curve, AUC)는 약동학에서 사용되는 일반적인 파라미터\n    - 시간에 따른 약물 노출의 범위를 추정하는 데 사용\n    - 해당 기간 동안 혈중에서의 누적된 약물 농도를 나타냄\n\n - $C_{max}$    -  Maximum observed concentration, occurring at time Tmax, as defined above.\n    -  $T_{max}$에서의 최대 농도\n - $T_{max}$\n    - Time of maximum observed concentration. For non-steady-state data, the entire curve is considered. If the maximum observed concentration is not unique, then the first maximum is used.\n    - 최대 혈중 농도가 관찰된 시간\n    - 유일한 값이 아닌 경우 첫번재 값 사용\n \n- $\\lambda_z$\n    - First-order rate constant associated with the terminal (log-linear) portion of the curve. \nEstimated by linear regression of time vs. log concentration\n    - 곡선의 말단(로그-선형) 부분과 관련된 1차 속도상수는 시간 대 로그 농도의 선형 회귀를 통해 추정\n    - 곡선의 로그-선형 영역에서 시간과 로그 농도 간의 선형 관계를 분석하여 얻어진 1차 속도상수\n    - 약동학 데이터의 로그-선형 부분에서 시간 대 로그 농도의 관계를 선형 회귀하여 추정된 1차 속도상수를 의미.\n- $ln(2)/\\lambda_z$\n    -  Terminal half-life\n\n- $Tau$\n    -  Available in the Dosing Used results worksheet for steady-state data. The (assumed equal) dosing interval for steady-state data.\n    -  반복 투여하는 연구에서 반복투여하는 간격\n    -  예) 12시간 간격으로 하루에 두 번 투여시, tau = 12\n\n- $AUC_{TAU}$\n    - The partial area from dosing time to dosing time plus Tau. See “Partial area calculation”\n    - for information on how it is computed\n    - tau간격 별로 혈중 농도 곡선 하 면적.\n\n-$\\text{ Swing}$: Cmax – Cmn/Cmin\n\n-$\\text{ Fluctuation}$ \n\n- 100(Cmax – Cmin)/Cavg\n-  where Cmin and Cmax were obtained between dosing time and dosing time plus Tau\n- 약물 농도의 최소값($C_{min}$)과 최대값($C_{max}$) 사이의 변동을 약물 투여 간격 내에서 평균 농도($C_{avg}$)에 대한 백분율로 나타내는 약동학적 파라미터 .\n\n\n\n약동학 파라메터 산출 프로그램 윈놀린 가이드 참고^[https://onlinehelp.certara.com/phoenix/8.3/responsive_html5_!MasterPage!/WinNonlin%20User%27s%20Guide.pdf]\n\n- page 146 정도부터 파라메터 설명 및 계산법 확인\n\n아래는 식품의약품 안전처 규칙 내용 중 일부\n\n- AUCt: 투약시간부터 최종 혈중농도 정량 시간 t까지의 혈중농도-시간곡선하면적\n- AUC∞ : 투약시간부터 무한시간까지의 혈중농도-시간곡선하면적 (AUC∞ = AUCt + Ct/λZ\n- Ct : 최종정량농도\n- λZ : 말단 소실 정수\n- AUCt/AUC∞ : AUCt의 AUC대한 비\n- t1/2β : 소실 반감기\n- AUCτ : 정상상태의 투여간격τ중의 혈중농도-시간 곡선하면적\n- Cmax :최고혈중농도\n- Css,max정상상태의 최고혈중농도\n- Css,m: 정상상태의 최저혈중농도\n\n**동등성 기준 : Tmax를 제외한 대조약과 시험약의 비교평가항목치를 로그변환하여 통계처리 하였을 때, 로그변환한 평균치 차의 90% 신뢰구간이 log 0.8에서 log 1.25 이내이어야 한다**\n\n## 2 x 2 Crossover Design\n\n현재 식품의약품 안전처에서는 두 제제의 생동성 평가 방법으로 2 x 2 교차설계법을 이용하여 두 제제의 생체이용률의 평균을 비교하는 방법 사용\n\n|    | Period 1 | Period 2  |\n|:----:|:----------:|:-----------:|\n|Sequence 1| Reference|Test|\n|Sequence 2|Test|Reference|\n\n$$y_{jkl} = \\mu + g_j + S_{l(j)} + p_k + \\pi_{jk} + \\epsilon_{jkl}$$\n\n$$j = 1,2; k = 1,2; l=1,2, \\dots, n_{1j}$$\n\n$$S_{l(j)} \\sim iid N(0,\\sigma^2_s) , \\epsilon_{jkl} \\sim iid N(0, \\sigma^2_\\epsilon)$$\n\n### 혈중 농도 곡선 예시\n\n사다리꼴 공식으로 AUC 계산\n\n데이터 설명\n\n- Subject: 대상자\n- Sequence: 순서군\n- Period: 시기군\n- Concentration: 혈중농도\n- Treatment: 치료군\n\n`해석`\n\n- Trearmet의 p값은 0.05보다 큼. 치료 효과는 유의하지 않다.\n- Period의 p값은 0.05보다 큼, 시기효과는 유의하지 않다.\n- Sequence의 p값은 0.05보다 큼, 순서효과는 유의하지 않다.\n"},"formats":{"html":{"identifier":{"display-name":"HTML","target-format":"html","base-format":"html"},"execute":{"fig-width":7,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":true,"echo":true,"output":true,"warning":true,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":false,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"engine":"jupyter"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":false,"code-overflow":"scroll","code-link":false,"code-line-numbers":false,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[],"notebook-links":true},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","to":"html","css":["../../styles.css"],"toc":true,"output-file":"2023-06-15-PK Analysis.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words"},"metadata":{"lang":"en","fig-responsive":true,"quarto-version":"1.4.315","theme":"pulse","code-copy":false,"title-block-banner":true,"comments":{"utterances":{"repo":"seoyeonc/md"}},"title":"Pharmacokinetic Analysis","author":"SEOYEON CHOI","date":"2023-06-09","bibliography":["ref.bib"],"categories":["Pharmacokinetic Analysis"]},"extensions":{"book":{"multiFile":true}}},"ipynb":{"identifier":{"display-name":"Jupyter","target-format":"ipynb","base-format":"ipynb"},"execute":{"fig-width":7,"fig-height":5,"fig-format":"png","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":true,"echo":true,"output":true,"warning":true,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":false,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"engine":"jupyter"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"ipynb","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":false,"code-tools":false,"tbl-colwidths":true,"merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"default-image-extension":"png","to":"ipynb","output-file":"2023-06-15-PK Analysis.ipynb"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words"},"metadata":{"title-block-banner":true,"comments":{"utterances":{"repo":"seoyeonc/md"}},"title":"Pharmacokinetic Analysis","author":"SEOYEON CHOI","date":"2023-06-09","bibliography":["ref.bib"],"categories":["Pharmacokinetic Analysis"]}}},"projectFormats":["html"]}